Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sangamo Therapeutics, Inc. - Common Stock
(NQ:
SGMO
)
0.1776
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sangamo Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
July 24, 2024
Via
Benzinga
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results
↗
July 24, 2024
Via
Benzinga
Topics
Stocks
4 Analysts Assess Sangamo Therapeutics: What You Need To Know
↗
March 13, 2024
Via
Benzinga
Deep Dive Into Sangamo Therapeutics Stock: Analyst Perspectives (4 Ratings)
↗
January 19, 2024
Via
Benzinga
Where Sangamo Therapeutics Stands With Analysts
↗
November 06, 2023
Via
Benzinga
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
↗
July 24, 2024
Pfizer's Phase 3 AFFINE study of giroctocogene fitelparvovec gene therapy for hemophilia A meets key endpoints, showing a significant reduction in annualized bleeding rate.
Via
Benzinga
Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate
July 24, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
July 11, 2024
Via
AB Newswire
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
↗
May 15, 2024
Via
Benzinga
SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024
↗
May 09, 2024
SGMO stock results show that Sangamo Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
May 09, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
May 09, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
May 02, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
April 22, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
↗
March 22, 2024
Via
Benzinga
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
March 22, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
↗
March 19, 2024
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term...
Via
Benzinga
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
March 13, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For March 13, 2024
↗
March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
Via
Benzinga
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
March 12, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
↗
February 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
February 12, 2024
Via
Benzinga
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
February 12, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Why Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
↗
February 06, 2024
Shares of Palantir Technologies Inc. (NYSE: PLTR) rose sharply during today’s pre-market trading after the company reported better-than-expected fourth-quarter sales results and issued guidance.
Via
Benzinga
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
February 05, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
January 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
January 10, 2024
Via
Benzinga
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
November 15, 2023
Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
